Human Papillomavirus Protein E7 (E7) - Pipeline Review, H2 2016

Published: Nov, 2016 | Pages: 116 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Human Papillomavirus Protein E7 (E7) - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Human Papillomavirus Protein E7 (E7) - Pipeline Review, H2 2016', provides in depth analysis on Human Papillomavirus Protein E7 (E7) targeted pipeline therapeutics. 

The report provides comprehensive information on the Human Papillomavirus Protein E7 (E7) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Human Papillomavirus Protein E7 (E7) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: 
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
*Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for Human Papillomavirus Protein E7 (E7) 
- The report reviews Human Papillomavirus Protein E7 (E7) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Human Papillomavirus Protein E7 (E7) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Human Papillomavirus Protein E7 (E7) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Human Papillomavirus Protein E7 (E7) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Human Papillomavirus Protein E7 (E7) 
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Human Papillomavirus Protein E7 (E7) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Human Papillomavirus Protein E7 (E7) Overview 9
Therapeutics Development 10
Human Papillomavirus Protein E7 (E7) - Products under Development by Stage of Development 10
Human Papillomavirus Protein E7 (E7) - Products under Development by Therapy Area 11
Human Papillomavirus Protein E7 (E7) - Products under Development by Indication 12
Human Papillomavirus Protein E7 (E7) - Pipeline Products Glance 13
Late Stage Products 13
Early Stage Products 14
Unknown Stage Products 15
Human Papillomavirus Protein E7 (E7) - Products under Development by Companies 16
Human Papillomavirus Protein E7 (E7) - Products under Development by Universities/Institutes 20
Human Papillomavirus Protein E7 (E7) - Therapeutics Assessment 22
Assessment by Monotherapy/Combination Products 22
Assessment by Mechanism of Action 23
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Human Papillomavirus Protein E7 (E7) - Companies Involved in Therapeutics Development 28
Abion Inc 28
Advaxis Inc 29
Bioleaders Corporation 30
BioNTech AG 31
Cancer Research Technology Ltd 32
Etubics Corp 33
Formune SL 34
Genexine Inc 35
Genticel S.A. 36
iBio Inc 37
Immunovaccine Inc 38
Inovio Pharmaceuticals Inc 39
Kite Pharma Inc 40
MedImmune LLC 41
Selecta Biosciences Inc 42
Tomegavax Inc 43
Transgene SA 44
VLPbio 45
Human Papillomavirus Protein E7 (E7) - Drug Profiles 46
ABN-301 - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
Antibodies to Inhibit E7 for HPV Associated Cancer - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
Aptamer to Target HPV E7 Protein for Cervical Cancer - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
axalimogene filolisbac - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
BLSILSB-710c - Drug Profile 66
Product Description 66
Mechanism Of Action 66
R&D Progress 66
Cellular Immunotherapy to Target HPV-16 E7 Protein for Head and Neck Cancer and Cervical Cancer - Drug Profile 67
Product Description 67
Mechanism Of Action 67
R&D Progress 67
CerviVax - Drug Profile 69
Product Description 69
Mechanism Of Action 69
R&D Progress 69
DPXE-7 - Drug Profile 70
Product Description 70
Mechanism Of Action 70
R&D Progress 70
EDA-HPVE7 - Drug Profile 71
Product Description 71
Mechanism Of Action 71
R&D Progress 71
Enzymes to Inhibit HPV E7 for Human Papillomavirus Related Cervical Cancer - Drug Profile 72
Product Description 72
Mechanism Of Action 72
R&D Progress 72
ETBX-041 - Drug Profile 73
Product Description 73
Mechanism Of Action 73
R&D Progress 73
GLBL-101c - Drug Profile 74
Product Description 74
Mechanism Of Action 74
R&D Progress 74
GTL-001 - Drug Profile 76
Product Description 76
Mechanism Of Action 76
R&D Progress 76
GTL-002 - Drug Profile 79
Product Description 79
Mechanism Of Action 79
R&D Progress 79
GX-188E - Drug Profile 80
Product Description 80
Mechanism Of Action 80
R&D Progress 80
human papillomavirus [Serotype 16] vaccine - Drug Profile 82
Product Description 82
Mechanism Of Action 82
R&D Progress 82
human papillomavirus [serotype 16] vaccine 2 - Drug Profile 83
Product Description 83
Mechanism Of Action 83
R&D Progress 83
human papillomavirus [serotypes 16] vaccine - Drug Profile 84
Product Description 84
Mechanism Of Action 84
R&D Progress 84
human papillomavirus vaccine - Drug Profile 85
Product Description 85
Mechanism Of Action 85
R&D Progress 85
INO-3106 - Drug Profile 86
Product Description 86
Mechanism Of Action 86
R&D Progress 86
INO-3112 - Drug Profile 87
Product Description 87
Mechanism Of Action 87
R&D Progress 87
PVX-01 - Drug Profile 90
Product Description 90
Mechanism Of Action 90
R&D Progress 90
SEL-701 - Drug Profile 91
Product Description 91
Mechanism Of Action 91
R&D Progress 91
TA-CIN - Drug Profile 92
Product Description 92
Mechanism Of Action 92
R&D Progress 92
TG-4001 - Drug Profile 93
Product Description 93
Mechanism Of Action 93
R&D Progress 93
Vaccine for HPV Associated Cervical Cancer - Drug Profile 95
Product Description 95
Mechanism Of Action 95
R&D Progress 95
Vaccine to Target HPV E7 Protein for Cervical Cancer - Drug Profile 96
Product Description 96
Mechanism Of Action 96
R&D Progress 96
Vaccine to Target IL-2 and E7 Protein for Cervical Cancer and Oropharyngeal Cancer - Drug Profile 97
Product Description 97
Mechanism Of Action 97
R&D Progress 97
VGX-3100 - Drug Profile 98
Product Description 98
Mechanism Of Action 98
R&D Progress 98
Vvax-001 - Drug Profile 101
Product Description 101
Mechanism Of Action 101
R&D Progress 101
Human Papillomavirus Protein E7 (E7) - Dormant Projects 102
Human Papillomavirus Protein E7 (E7) - Discontinued Products 104
Human Papillomavirus Protein E7 (E7) - Featured News & Press Releases 105
Nov 14, 2016: Inovios Cancer Immunotherapy (INO-3112) Generates T Cell Immune Responses in Tumor Tissue and Peripheral Blood in Patients with HPV-Associated Head and Neck Cancer 105
Nov 11, 2016: Advaxis to Present Phase 1 Combination Data and New Preclinical Data Using AXAL at Upcoming Society for Immunotherapy of Cancer (SITC) 2016 Annual Meeting 106
Oct 24, 2016: Inovio Announces FDA Request for Additional Information For Phase III Program; Trial Initiation Delayed 107
Oct 24, 2016: Advaxis Announces GOG-0265 12-month Overall Survival Rate of 37.5% in Stage 2 107
Oct 20, 2016: Advaxis Initiates Phase 3 Study of Axalimogene Filolisbac 108
Oct 12, 2016: Inovio Expands Executive Team to Advance its DNA Immunotherapy Product Portfolio 109
Oct 11, 2016: Advaxis Research Reception at SITC 2016 to Review Recent AXAL Highlights and the AXAL-Durvalumab Combination Poster 110
Sep 26, 2016: Advaxis' Lm Technology Immunotherapies to be Showcased in Three Poster Presentations at SITC Annual Meeting 110
Aug 11, 2016: Advaxis Announces that Phase 2 Head and Neck Cancer Study with AXAL Advances to Second Stage 110
Jul 26, 2016: Phase 1/2 Combination Trial of AXAL and Durvalumab Completes Second Dose-Escalation Cohort 111
Jul 21, 2016: Advaxis AXAL Receives Fast Track Designation by the FDA as Adjuvant Therapy for High-Risk Locally Advanced Cervical Cancer Patients 111
Jul 18, 2016: European Medicines Agency Committee Classifies Advaxis' Axalimogene Filolisbac as an Advanced-Therapy Medicinal Product 112
Jul 06, 2016: FDA Grants Special Protocol Assessment to Advaxis Phase 3 Study of AXAL in Patients with Cervical Cancer 113
Jul 06, 2016: Genticel Appoints Eumedix as Strategic Advisor to Support Company'S Access to Innovative Drug Candidates 114
Jun 23, 2016: Genticel Reports 18 Month Interim Analysis of GTL001 Phase 2 Trial in HPV16/18 Infected Women 114
Appendix 115
Methodology 115
Coverage 115
Secondary Research 115
Primary Research 115
Expert Panel Validation 115
Contact Us 115
Disclaimer 116

List of Tables

Number of Products under Development for, H2 2016 10
Number of Products under Development by Therapy Area, H2 2016 11
Number of Products under Development by Indication, H2 2016 12
Comparative Analysis by Late Stage Development, H2 2016 13
Comparative Analysis by Early Stage Products, H2 2016 14
Comparative Analysis by Unknown Stage Development, H2 2016 15
Number of Products under Development by Companies, H2 2016 16
Products under Development by Companies, H2 2016 17
Products under Development by Companies, H2 2016 (Contd..1) 18
Products under Development by Companies, H2 2016 (Contd..2) 19
Number of Products under Investigation by Universities/Institutes, H2 2016 20
Products under Investigation by Universities/Institutes, H2 2016 21
Assessment by Monotherapy/Combination Products, H2 2016 22
Number of Products by Stage and Mechanism of Action, H2 2016 23
Number of Products by Stage and Route of Administration, H2 2016 25
Number of Products by Stage and Molecule Type, H2 2016 27
Pipeline by Abion Inc, H2 2016 28
Pipeline by Advaxis Inc, H2 2016 29
Pipeline by Bioleaders Corporation, H2 2016 30
Pipeline by BioNTech AG, H2 2016 31
Pipeline by Cancer Research Technology Ltd, H2 2016 32
Pipeline by Etubics Corp, H2 2016 33
Pipeline by Formune SL, H2 2016 34
Pipeline by Genexine Inc, H2 2016 35
Pipeline by Genticel S.A., H2 2016 36
Pipeline by iBio Inc, H2 2016 37
Pipeline by Immunovaccine Inc, H2 2016 38
Pipeline by Inovio Pharmaceuticals Inc, H2 2016 39
Pipeline by Kite Pharma Inc, H2 2016 40
Pipeline by MedImmune LLC, H2 2016 41
Pipeline by Selecta Biosciences Inc, H2 2016 42
Pipeline by Tomegavax Inc, H2 2016 43
Pipeline by Transgene SA, H2 2016 44
Pipeline by VLPbio, H2 2016 45
Dormant Projects, H2 2016 102
Dormant Projects (Contd..1), H2 2016 103
Discontinued Products, H2 2016 104